Hemophilia B

Several hematologists will be honored during this year’s ASH Annual Meeting.

The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia.

The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B.

Lindsey A. George, MD, discussed “exciting” preclinical data on gene editing for hemophilia B, which was presented in a session at ASH Annual Meeting and Exposition.

Elderly individuals with moderate or severe hemophilia had poorer joint or functional status and greater joint pain sensitivity than those with mild hemophilia or healthy controls, according to study results.

Prophylactic concizumab conferred significant reductions in treated spontaneous and traumatic bleeds among patients with hemophilia A or B without inhibitors, a primary analysis of the randomized phase 3 explorer8 study showed.

Marstacimab reduced annualized bleeding rate compared with prophylaxis and on-demand IV regimens for patients with hemophilia A or B, according to the agent’s manufacturer.

Etranacogene dezaparvovec conferred superior bleed control for adults with moderate or severe hemophilia B compared with standard factor IX prophylaxis, according to results of the phase 3 HOPE-B study.

In this edition, disparities among women in the surgical workforce, GSK withdraws belantamab mafodotin from US market, risk for lymphoma low after postmastectomy reconstruction, and more.

The FDA approved etranacogene dezaparvovec-drlb, a single-dose gene therapy for treatment of adults with hemophilia B.